Minimal Determinant Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic Antitumor Cytolytic T Lymphocyte Responses

Cancer Research

Volumn 55, Issue 8, 1995, Pages 1741-1747

  McCabe, Barbra Jill ^a,b   Irvine, Kari R ^a   Nishimura, Michael I ^a   Yang, James C ^a   Spiess, Paul J ^a   Shulman, Eliza P ^a   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; OVALBUMIN; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS RECOMBINATION;

ANIMAL; BASE SEQUENCE; CHICKENS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; RECOMBINANT PROTEINS; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; THYMUS NEOPLASMS; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0028930719     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Prehn, R. T., and Main, J. M. Immunity to mcthylcholanthrcne-induced sarcomas. J. Natl. Cancer Inst., 18: 769–778, 1957.
2. Klein, G., Sjögren, H. O., Klein, E., and Hellström, K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res., 20: 1561–1572, 1960.
3. Greenberg, P. D., Cheever, M. A., and Fefer, A. H-2 restriction of adoptive immunotherapy of advanced tumors. J. Immunol, 126: 2100–2103, 1981.
4. Itoh, K., Platsoucas, D. C., and Balch, C. M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: activation by interleukin 2 and autologous tumor cells and involvement of the T cell receptor. J. Exp. Med., 168: 1419–1441, 1988.
5. Muul, L. M., Spiess, P. J., Director, E. P., and Rosenberg, S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol., 138: 989–995, 1987.
6. Greenberg, P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49: 281–355, 1991.
7. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., and White, D. E. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med., 319: 1676–1680, 1988.
8. Pardoll, D. M. Tumour antigens. A new look for the 1990s. Nature (Lond.), 369: 357–359, 1994.
9. Houghton, A. N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med., 180: 1–4, 1994.
10. Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E., and Boon, T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med., 173: 1373–1384, 1991.
11. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643–1647, 1991.
12. Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., Coulie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178:489–495,1993.
13. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515–3519, 1994.
14. Kawakami, Y., Eliyahu, S., Delgado, S. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91: 6458–6462, 1994.
15. Robbins, P. F., El-Gamil, M., Kawakami, Y., and Rosenberg, S. A. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res., 54: 3124–3126, 1994.
16. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Washington DC), 264: 716–719, 1994.
17. Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., and Cheever, M. A. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-21 neu protooncogene protein. Cancer Res., 54: 1071–1076, 1994.
18. Peace, D. J., Smith, J. W., Chen, W., You, S. G., Cosand, W. L., Blake, J., and Cheever, M. A. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J. Exp. Med., 179: 473–479, 1994.
19. Houbiers, J. G., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J., Brand, A., Momburg, F., Kast, W. M., and Melief, C. J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23: 2072–2077, 1993.
20. Melief, C. J., and Kast, W. M. Potential immunogenicity of oncogene and tumor suppressor gene products. Curr. Opin. Immunol., 5: 709–713, 1993.
21. Jung, S., and Schluesener, H. J. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J. Exp. Med., 173: 273–276, 1991.
22. Townsend, A. M., Rothbard, J., Gotch, F. M., Bahdur, G., Wraith, D., and Mc-Michael, A. J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell, 44: 959–968, 1986.
23. Townsend, A., and Bodmer, H. Antigen recognition of class I restricted T lymphocytes. Annu. Rev. Immunol., 7: 601–624, 1989.
24. Falk, K., Rötzschke, O., Stevanovic, S., Jung, G., and Rammensee, H-G. Allele-speeifie motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.), 351: 290–296, 1991.
25. Falk, K., Rötzschke, O., Deres, K., Metzger, J., Jung, G., and Rammensee, H.-G. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J. Exp. Med., 174: 425–434, 1991.
26. Yewdell, J. W., and Bennink, J. R. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv. Immunol., 52: 1–123, 1992.
27. Deres, K., Schild, H., Wiesmuller, K.-H., Jung, G., and Rammensee, H.-G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (Lond.), 342: 561–564, 1989.
28. Romero, P., Eberl, G., Casanova, J. L., Cordey, A. S., Widmann, C., Luescher, I. F., Corradin, G., and Maryanski, J. L. Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule. J. Immunol., 148: 1871–1878, 1992.
29. Schulz, M., Zinkernagel, R. M., and Hengartner, H. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA, 88: 991–993, 1991.
30. Skipper, J., and Stauss, H. J. Identification of two cytotoxic T lymphocyte-recognized epitopes in the ras protein. J. Exp. Med., 777: 1493–1498, 1993.
31. Schild, H., Norda, M., Deres, K., Falk, K., Rotzschke, O., WiesmuUer, K. H., Jung, G., and Rammensee, H. G. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J. Exp. Med., 174: 1665–1668, 1991.
32. Berzofeky, J. A. Epitope selection and design of synthetic vaccines. Molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines. Ann. NY Acad. Sci., 690: 256–264, 1993.
33. Moore, M. W., Carbone, F. R., and Bevan, M. J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell, 54: 777–785,1988.
34. Lipford, G. B., Hoffman, M., Wagner, H., and Heeg, K. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J. Immunol., 750: 1212–1222, 1993.
35. Reddy, R., Zhou, F., Nair, S., Huang, L., and Rouse, B. T. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol., 148: 1585–1589, 1992.
36. Zhou, F., Rouse, B. T., and Huang, L. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res., 52: 6287–6291, 1992.
37. Rotzschke, O., Falk, K., Stevanovic, S., Jung, G., Walden, P., and Rammensee, H. G. Exact prediction of a natural T cell epitope. Eur. J. Immunol., 27: 2891–2894,1991.
38. Shastri, N., and Gonzalez, F. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J. Immunol., 750: 2724–2736, 1993.
39. Moss, B. Vaccinia virus: a tool for research and vaccine development. Science (Washington DC), 252: 1662–1667, 1991.
40. Estin, C. D., Stevenson, U. S., Plowman, G. D., Hu, S. L., Sriddar, P., Hellstrom, L, Brown, J. P., and Hellstrom, K. E. Recombinant vaccinia virus vaccine against human melanoma antigen p97 for use in immunotherapy. Proc. Natl. Acad. Sci. USA, 85: 1052–1056, 1988.
41. Kantor, J., Irvine, K., Abrams, S., Kaufman, H., DiPietro, J., and Schlom, J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst., 84: 1084–1091, 1992.
42. Restifo, N. P., Esquivel, F., Asher, A. L., Stötter, H., Barth, R. J., Bennink, J. R., Mule, J. J., Yewdell, J. W., and Rosenberg, S. A. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an antitumor immune response. J. Immunol., 747: 1453–1459, 1991.
43. Michalek, M. T., Grant, E. P., Gramm, C., Goldberg, A. L., and Rock, K. L. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature (Lond.), 363: 552–554, 1993.
44. Eisenlohr, L. C., Bacik, I., Bennink, J. R., Bernstein, K., and Yewdell, J. W. Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes. Cell, 77: 963–972, 1992.
45. Kozak, M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J. Biol. Chem., 266: 19867–19870, 1991.
46. Bennink, J. R., and Yewdell, J. W. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr. Top. Microbiol. Immunol., 163: 153–184, 1990.
47. Barth, R. J., Bock, S. N., Mule, J. J., and Rosenberg, S. A. Unique murine tumor associated antigens identified by tumor infiltrating lymphocytes. J. Immunol., 144: 1531–1537, 1990.
48. Mule, J. J., Yang, J. C., Lafreniere, R., Shu, S., and Rosenberg, S. A. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J. Immunol., 139: 285–294, 1987.
49. Restifo, N. P., Bacik, I., Irvine, K. R., YewdeU, J. W., McCabe, B. J., Anderson, R. W., Eisenlohr, L. C., Rosenberg, S. A., and Bennink, J. R. Antigen processing in vivo and the elicitation of primary cytotoxic T lymphocyte responses. J. Immunol., in press, 1995.
50. Minev, B. R., McFarland, B. J., Spiess, P. J., Rosenberg, S. A., and Restifo, N. P. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res., 54: 4155–4164, 1994.
51. Lawson, C. M., Bennink, J. R., Restifo, N. P., Yewdell, J. W., and Murphy, B. R. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J. Virol., 68: 3505–3511, 1994.
52. Barth, R. J., Mule, J. J., Spiess, P. J., and Rosenberg, S. A. Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor infiltrating lymphocytes. J. Exp. Med., 173: 647–658, 1991.
53. Schwartzentruber, D. J., Topalian, S. L., Mancini, M. J., and Rosenberg, S. A. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-γ by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J. Immunol., 146: 3674–3681, 1991.
54. Irvine, K. R., McCabe, B. J., Rosenberg, S. A., and Restifo, N. P. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic cytolytic T lymphocytes. J. Immunol., in press, 1995.
55. Shively, J., and Beatty, J. CEA-related antigens: molecular biology and significance. Crit. Rev. Oncol. Hematol., 2: 355–399, 1985.